NASDAQ:SESN Sesen Bio (SESN) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free SESN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.63▼$12.9952-Week Range N/AVolume93,330 shsAverage Volume1.07 million shsMarket Capitalization$2.56 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sesen Bio alerts: Email Address Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Sesen Bio Stock (NASDAQ:SESN)Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Read More Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. SESN Stock News HeadlinesAugust 4, 2023 | fool.comSesen Bio (NASDAQ: SESN)March 6, 2023 | bizjournals.comAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 2, 2023 | msn.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | finance.yahoo.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsFebruary 28, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 24, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 21, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 17, 2023 | stockhouse.comBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 16, 2023 | businesswire.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | finance.yahoo.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 15, 2023 | finance.yahoo.com5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 14, 2023 | bizjournals.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | msn.comSesen gains 11% on amended terms for merger with CarismaFebruary 14, 2023 | finance.yahoo.comSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerFebruary 6, 2023 | finance.yahoo.comSesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years agoFebruary 2, 2023 | finance.yahoo.comSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerFebruary 2, 2023 | finance.yahoo.comThe Petri Dish: Departed White House adviser returns to the BroadJanuary 30, 2023 | finance.yahoo.comSesen Bio Receives NASDAQ Delisting NoticeJanuary 26, 2023 | finance.yahoo.comSesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of StockholdersJanuary 19, 2023 | finance.yahoo.comSesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma TherapeuticsJanuary 6, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing InvestigationsJanuary 5, 2023 | finance.yahoo.comInvestor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma MergerJanuary 4, 2023 | finance.yahoo.comSesen Bio Reiterates Confidence in Pending Merger with Carisma TherapeuticsJanuary 3, 2023 | msn.comSesen Bio investors reiterate plan to vote against Carisma mergerSee More Headlines Receive SESN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SESN CUSIPN/A CIK1485003 Webwww.sesenbio.com Phone(617) 444-8550Fax617-858-0911Employees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax Margin-59.40% Return on Equity6.70% Return on Assets5.41% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.10 Sales & Book Value Annual Sales$40 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.39 Book Value$0.78 per share Price / BookN/AMiscellaneous Outstanding Shares203,490,000Free Float196,980,000Market Cap$2.56 billion OptionableOptionable Beta0.83 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesThomas R. CannellPresident, Chief Executive Officer & DirectorMonica ForbesChief Financial Officer & TreasurerStephanie VigueFinance DirectorJeannick CizeauHead of ResearchGlen C. MacDonaldChief Technology OfficerKey CompetitorsCorcept TherapeuticsNASDAQ:CORTEvotecNASDAQ:EVOMerusNASDAQ:MRUSGemini TherapeuticsNASDAQ:GMTXSummit TherapeuticsNASDAQ:SMMTView All Competitors SESN Stock Analysis - Frequently Asked Questions How were Sesen Bio's earnings last quarter? Sesen Bio, Inc. (NASDAQ:SESN) released its earnings results on Sunday, November, 7th. The company reported $7.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.40) by $8.60. When did Sesen Bio's stock split? Sesen Bio's stock reverse split before market open on Wednesday, March 8th 2023. The 1-20 reverse split was announced on Wednesday, March 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Sesen Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK). This page (NASDAQ:SESN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sesen Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.